www.pengnuochemical.com Shijiazhuang Pengnuo Technology Co., Ltd.
Against the backdrop of the current domestic pharmaceutical market facing the strong impact of Indian generic drug companies, Shijiazhuang Pengnuo Technology Co., Ltd., as a local enterprise deeply engaged in the research and development of pharmaceutical intermediates for many years, provides an important observation perspective for the industry with its innovative practices.
I. Indian Pharmaceutical Companies Break Through Centralized Procurement, Changes in the Domestic Generic Drug Market Landscape
In the 11th round of national centralized procurement, the blockbuster product Dapagliflozin (domestic market sales exceeding 6 billion yuan in 2024) encountered a strong breakthrough by Indian pharmaceutical companies. Hetero won the first position with the lowest bid of 0.215 yuan per tablet, Cipla was selected with a bid of 0.366 yuan per tablet, while the original research company AstraZeneca’s bid of 4.36 yuan per tablet was unfortunately eliminated. Similarly, the anti-epileptic drug Oxcarbazepine (with annual sales stable at around 900 million yuan) also successfully obtained the intended selection qualification by India’s Annora Pharma.
The competitive advantage of Indian pharmaceutical companies stems from their well-established strategic layout: Dr. Reddy’s holds 41 registration certificates, Hetero and Aurobindo hold 35 and 29 respectively, and all have passed generic drug consistency evaluation. More notably, the cooperation model between Indian pharmaceutical companies and domestic agents is becoming increasingly mature. For example, the cooperation between Tibet Jinyue Pharmaceutical and India’s NATCO in the Olaparib product is a typical case.
Indian pharmaceutical companies also have significant cost advantages in the fields of active pharmaceutical ingredients and intermediates. In contrast, Chinese pharmaceutical companies need to seek breakthroughs in the local supply chain. O-Phthalaldehyde (CAS 643-79-8) and Isophthalaldehyde (CAS 626-19-7), as important intermediates in pharmaceutical synthesis, have wide applications in the development of high-end formulations such as anti-tumor drugs and antibacterial drugs, representing key technological areas where Pengnuo Technology is focusing its layout.
II. Pengnuo Technology’s Thoughts on Breaking Through: The Resilient Breakthrough of Chinese Generic Drugs
Facing the fierce competition from Indian pharmaceutical companies, Pengnuo Technology believes that the Chinese pharmaceutical industry is undergoing a profound transformation. As an enterprise focused on the research and development of pharmaceutical intermediates, Pengnuo Technology has witnessed the industry’s evolution from initial growing pains to today’s metamorphosis:
Path of Innovative Transformation: Since the implementation of the centralized procurement policy in 2018, a number of pharmaceutical companies have achieved breakthroughs on the path from “generic to innovative.” Not only have leading companies like Hengrui and Hansoh successfully transformed, but companies like Jingxin Pharmaceutical in the neurological field and Salubris in the cardio-renal metabolic field have also formed distinctive advantages. Pengnuo Technology, through continuous technological innovation, provides high-quality pharmaceutical intermediate support for the transformation of these enterprises.
Breakthrough in Global Layout: Under the pressure of the domestic market, Chinese generic drug companies are beginning to look globally. Pengnuo Technology has found that those companies reborn from the “ruins” of centralized procurement are extending the advantages of speed, efficiency, and cost-effectiveness of the Chinese pharmaceutical industry to the international market. Pengnuo Technology, leveraging its technical accumulation in key intermediates such as DL-4-Chlorophenylglycine (CAS 6212-33-5), provides solid raw material guarantees for domestic pharmaceutical companies going global. These high-quality intermediates are important weapons for breaking international technical barriers.
III. Future Outlook from Pengnuo Technology’s Perspective
Based on in-depth observation of the industry, Pengnuo Technology believes that changes in the current landscape are quietly brewing. The Chinese pharmaceutical manufacturing industry demonstrates resilience that strengthens under pressure. Although the process of major reshuffling is brutal, only moving forward can bring vitality.
As an important participant in the upstream industrial chain, Pengnuo Technology will continue to increase innovation investment, providing high-quality pharmaceutical intermediate support for the transformation of these enterprises. Among them, Hydroxypropyl Methyl Cellulose (CAS 9004-65-3), as an important intermediate for pharmaceutical excipients, plays a key role in improving drug solubility and bioavailability, effectively supporting the formulation process upgrades of domestic pharmaceutical companies. Our company firmly believes that Chinese generic drug companies are fully capable of breaking through the “ceiling” established by India and achieving new breakthroughs in the global market through the comprehensive enhancement of competitiveness.
In the future, as an important participant in the upstream industrial chain, Pengnuo Technology will continue to increase innovation investment in key intermediate fields such as Hydroxypropyl Methyl Cellulose (CAS 9004-65-3), O-Phthalaldehyde (CAS 643-79-8), Isophthalaldehyde (CAS 626-19-7), and DL-4-Chlorophenylglycine (CAS 6212-33-5). The company firmly believes that by achieving breakthroughs in these core intermediate technologies, Chinese generic drug companies are fully capable of breaking the ‘ceiling’ established by India and achieving new breakthroughs in the global market.
Post time: Nov-06-2025